Platelet-Rich Plasma (PRP) Improves Erectile Function: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Area of Science:

• Regenerative Medicine
• Urology
• Andrology

Background:

• Animal studies suggest platelet-rich plasma (PRP) can address erectile dysfunction (ED) mechanisms.
• PRP contains growth factors that may promote tissue repair and vascularization.

Purpose of the Study:

• To evaluate the efficacy and safety of intracavernosal PRP injections for mild to moderate ED.
• To conduct the first double-blind, randomized, placebo-controlled trial on PRP for ED.

Main Methods:

• Sixty patients with mild/moderate ED received two sessions of intracavernosal PRP (n=30) or placebo (n=30) injections.
• Evaluations of erectile function using the IIEF-EF and safety were performed at 1, 3, and 6 months post-treatment.

Main Results:

• A significantly higher proportion of patients in the PRP group achieved minimal clinically important difference (MCID) in IIEF-EF at 6 months (69% vs. 27%).
• The PRP group showed statistically significant improvements in IIEF-EF scores at all time points compared to placebo.
• No adverse events were reported in the PRP group during the study.

Conclusions:

• Intracavernosal PRP injections represent a safe and effective short-term therapeutic option for managing mild to moderate ED.
• PRP may become a valuable addition to the urologist's treatment options for ED, warranting further investigation.